InvestorsHub Logo

Cindylou822

05/27/22 7:55 AM

#209534 RE: Cindylou822 #209533

The double edged sword for that would be that if the FDA realized that, it wouldn't give them a clear read on safety. Needed the lab results for that.

misiu143

05/27/22 8:05 AM

#209539 RE: Cindylou822 #209533

Yes , there patients are different then Veru , It was in patients with
Acute Respiratory Distress Syndrome , where mortality is 35-40%.

But not in moderate and not in severe patients..